Resources from the same session
LBA27 - Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study
Presenter: Thomas Powles
Session: Proffered Paper session - Genitourinary tumours, non-prostate 1
Resources:
Abstract
Slides
Webcast
651O - Phase II trial of pembrolizumab (P) in combination with sEphB4-HSA (B4) in previously treated metastatic urothelial carcinoma (mUC)
Presenter: Sarmad Sadeghi
Session: Proffered Paper session - Genitourinary tumours, non-prostate 1
Resources:
Abstract
Slides
Webcast
652O - Dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for patients with muscle-invasive bladder cancer (MIBC): Results of the GETUG/AFU VESPER V05 phase III trial
Presenter: Christian Pfister
Session: Proffered Paper session - Genitourinary tumours, non-prostate 1
Resources:
Abstract
Slides
Webcast
Q&A and live discussion
Presenter: Silke Gillessen
Session: Proffered Paper session - Genitourinary tumours, non-prostate 1
Resources:
Slides
Webcast
Invited Discussant 651O and 652O
Presenter: Enrique Grande
Session: Proffered Paper session - Genitourinary tumours, non-prostate 1
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Silke Gillessen
Session: Proffered Paper session - Genitourinary tumours, non-prostate 1
Resources:
Slides
Webcast